Who
Corazon (Corsee) D. Sanders
Director
Company insider
Files Form 4 as: Director, Legend Biotech; Director, Calidi Biotherapeutics; Director, Ultragenyx Pharmaceutical; Director, BeOne Medicines; Director, Molecular Templates.
In numbers
- Trades disclosed
- 54
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $2.7M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 19 Dec 2019
- Last trade
- 29 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 1 Oct 2026 | LEGN Legend BiotechBiotechnology | SEC FORM 4 Sold | $259K27,370 at $9.46 | filing |
| 24 Sep 2026filed 28 Sep 2026 | LEGN Legend BiotechBiotechnology | SEC FORM 4 Code A | —20,986 at $0.00 | filing |
| 24 Sep 2026filed 28 Sep 2026 | LEGN Legend BiotechBiotechnology | SEC FORM 4 Code A | —20,986 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | CLDI Calidi Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 15 Jun 2026filed 15 Jun 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $50K2,000 at $25.05 | filing |
| 15 Jun 2026filed 15 Jun 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $50K2,000 at $25.05 | filing |
| 22 May 2026filed 27 May 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $66K212 at $309.59 | filing |
| 22 May 2026filed 27 May 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $66K212 at $309.59 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,058 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,058 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 26 Nov 2025filed 1 Dec 2025 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —34,151 at $0.00 | filing |
| 26 Nov 2025filed 1 Dec 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code M | $418K2,627 at $159.03 | filing |
| 26 Nov 2025filed 1 Dec 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $620K1,823 at $340.20 | filing |
| 26 Nov 2025filed 1 Dec 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $275K804 at $342.47 | filing |
| 5 Sep 2025filed 9 Sep 2025 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —34,645 at $0.00 | filing |
| 5 Sep 2025filed 9 Sep 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code M | $415K2,665 at $155.68 | filing |
| 5 Sep 2025filed 9 Sep 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $898K2,665 at $337.00 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026Contrasting Legend Biotech (NASDAQ:LEGN) & Connect Biopharma (NASDAQ:CNTB)LEGN · tickerreport.com · 13 Oct 2026BeOne Medicines (NASDAQ:ONC) Price Target Raised to $420.00ONC · tickerreport.com · 10 Oct 2026Financial Analysis: Q32 Bio (NASDAQ:QTTB) versus Legend Biotech (NASDAQ:LEGN)LEGN · themarketsdaily.com · 6 Oct 2026
0 headlines in the last 90 days name Corazon (Corsee) D. Sanders; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.